Clinical Trials · NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 7,140
- Start date
- Dec 2025
- Locations
- 568 sites, 38 countries
- Primary endpoint
- Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events